Poor attainment of lipid targets in patients with symptomatic peripheral artery disease.

Dopheide, Jörn F.; Papac, Lucija; Schindewolf, Marc; Baumgartner, Iris; Drexel, Heinz (2018). Poor attainment of lipid targets in patients with symptomatic peripheral artery disease. Journal of clinical lipidology, 12(3), pp. 711-717. Elsevier 10.1016/j.jacl.2018.02.013

Text Dopheide_poor attainment.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (651kB) | Request a copy

BACKGROUND

Patients with peripheral artery disease (PAD) are at very high risk of future cardiovascular (CV) events. Strict lipid-lowering therapy is recommended. However, data on target level attainment are scarce.

OBJECTIVE

The objective of the study was to investigate guideline equitable lipid lowering in a large observational study of symptomatic PAD patients.

METHODS

Single-center observational study including 1109 patients with symptomatic PAD planned for revascularization at a tertiary university center. Between 2010 and 2017, guideline target level attainment trends over time and the association of statin therapy with CV mortality were analyzed.

RESULTS

Atorvastatin (52.3%) and rosuvastatin (23.5%) were the most frequently prescribed statins and amounted to an average simvastatin equivalent of 52 mg/d. Attainment rates of low-density lipoprotein cholesterol (LDL-C) and of non-high-density lipoprotein cholesterol goals were as low as 27% and 33%, respectively. Although there was a significant improvement of LDL-C from 2010 to 2017 (mean LDL-C 110 vs 80 mg/dL, P < .0001 for trend), attainment remained poor, that is, only 42% in 2016 and 45% in 2017 achieved the <70 mg/dL goal. CV mortality was significantly lower (4% vs 11%, P < .01) in statin-treated patients over a median follow-up period of 50 ± 26 months.

CONCLUSION

There is a remarkable undertreatment of LDL-C and non-high-density lipoprotein cholesterol in patients with symptomatic PAD, although LDL-C decreased significantly from 2010 to 2017. As statin treatment was associated with a reduced CV mortality rate, our findings call for an increased awareness in clinical lipidology regarding symptomatic PAD patients.

Interest & Impact

Downloads

2 since deposited on 20 Nov 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item